Alisertib Combination May Boost Metastatic Breast Cancer PFS
Adding alisertib to paclitaxel chemotherapy may improve progression-free survival for patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Adding alisertib to paclitaxel chemotherapy may improve progression-free survival for patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer
Breast cancer patients with distant lymph node metastases show survival outcomes similar to women with locoregional disease
Comprehensive next-generation sequencing can identify the primary tumour site in carcinoma of unknown origin, while patients with metastatic solid tumours may benefit from germline testing
Advanced urothelial cancer patients who have received a PD-1 or PD-L1 inhibitor and are unable to have cisplatin may benefit from enfortumab vedotin therapy
Metastatic pancreatic cancer patients do not gain a survival benefit from the use of ibrutinib alongside first-line chemotherapy
Metastatic non-small-cell lung cancer patients with a PD-L1 TPS score of 50% or higher do not benefit from use of ipilimumab alongside first-line pembrolizumab
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.